Menu
HARNESSING THE BENEFIT OF NOVEL CAR-T THERAPY
Pepromene Bio Inc

PEPROMENE BIO, INC.
PeproMene Bio, Inc. is a virtual, private biotech company located Irvine, California. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson Cancer Center, Houston, Texas and City of Hope National Medical Center, Duarte, California was licensed from City of Hope National Medical Center in April 2017...
Read More

Management Scientific Advisory Board

SCIENCE
BAFF (B cell activating factor), a soluble cytokine expressed by B cells is known for its proliferation and differentiation. In particular, BAFF-R (B cell activating factor receptor) is an excellent potential target for B-cell cancers not only because of its specificity on the BAFF, but also for its expression level by lymphoproliferative as well as leukemia-proliferative disorders. Successful discovery of anti-BAFF-R mAbs humanized C55 and C90 mAbs demonstrate high binding affinity to various NHLs. The BAFF-R CAR-T was constructed based on scFv antibodies using 2nd generation signaling domains... Read More

BAFF R CAR-T Cell Pipelines

CONTACT
PeproMene Bio, Inc.
15375 Barranca Pkwy. Suite A211
Irvine, CA 92618

T: 714-599-8077
Email: steve@pepromenebio.com
COPYRIGHT © 2017-2020 PeproMene Bio. Inc. ALL RIGHTS RESERVED